USA flag logo/image

An Official Website of the United States Government

Diagnostic array for aseptic encephalitis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43AI085650
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
AKONNI BIOSYSTEMS, INC.
400 Sagner Avenue Suite 300 FREDERICK, MD 21701-6082
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Diagnostic array for aseptic encephalitis
Agency: HHS
Contract: 1R43AI085650-01A1
Award Amount: $300,000.00
 

Abstract:

DESCRIPTION (provided by applicant): ABSTRACT Aseptic encephalitis and meningitis are potentially fatal diseases defined by acute swelling of the brain or protective membranes covering the brain and spinal cord. These diseases can be caused by viruses,bacteria, fungi and parasites. Viruses are the most common cause of encephalitis, with gt85% of all aseptic encephalitis caused by enterovirus. Human herpes viruses account for 4% of all viral infections, and West Nile virus is the most common of the arboviral infections in the U.S. According to the CDC, most cases of human enteroviral encephalitis resolve without complication. One the other hand, herpes simplex encephalitis results in rapid death in approximately 70% of cases if left untreated. Neisseriameningitides can be differentiated from other causes of meningitis by a rapidly spreading petechial rash, and other bacterial and fungal meningitis/encephalitis can readily be differentiated from viral causes by biochemistry and gram staining of the cerebrospinal fluid. Importantly, complications arising from CSF infection and appropriate treatment strategies depend on the type of infection and the species involved. For aseptic causes of the disease, case-adapted therapy is therefore dependent upon rapidlydiagnosing and differentiating between viral infections. Nucleic acid amplification and detection assays have been considered the test of choice for CSF infections for more than a decade, yet there are only three FDA-approved viral diagnostic tests, each of which only detects one virus at a time. The objective of this project is therefore to develop and trial a closed amplicon gel element RT-PCR array for the diagnosis of encephalitis and meningitis. The assay is based on a set of real- time PCR and reverse transcriptase PCR assays developed by the Laboratory of Viral Diseases at the Wadsworth Center. The performance goal for Phase 1 is a closed amplicon RT-PCR array for the detection of enterovirus, herpes viruses (HSV-1, HSV-2, VZV, CMV, HHV-6), and WestNile virus, with an analytical LoD of d 50 genome copies per reaction. The assay will contain an exogenously spiked, quantified extraction and amplification control which is amplified and detected in the same multiplex reaction. Successful completion of either Specific Aim in Phase 1 will warrant a Phase 2 proposal focused on reagent stability, packaging and shelf life; pre-clinical experiments to demonstrate assay reproducibility, repeatability, sensitivity and specificity; and developing automated algorithms and decision rules for assay data analysis and reporting. PUBLIC HEALTH RELEVANCE: The closed-amplicon gel element microarray will be the first-of-its-kind combination of RT-PCR and microarray technology in a simple, inexpensive test kit for the diagnosis of aseptic encephalities and meningits. The underlying platform developed herein will likewise find broad application in many areas of infectious disease diagnostics.

Principal Investigator:

Darrell P. Chandler
734-428-0713
dchandler@akonni.com

Business Contact:

Darrell P. Chandler
734-428-0713
dchandler@akonni.com
Small Business Information at Submission:

AKONNI BIOSYSTEMS, INC.
400 Sagner Avenue Suite 300 FREDERICK, MD -

EIN/Tax ID: 116166492
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No